Posted by Michael Wonder on 10 May 2018
Thousands of New Zealanders will benefit from advances in treatment
10 May 2018 - Thousands of New Zealanders will benefit from advances in treatment as a result of two PHARMAC funding decisions.
The first decision is to fund a medication for treating a degenerative eye condition, and the second is to fund another oral anticoagulant option for the prevention of strokes and the prevention or treatment of blood clots.
Aflibercept (Eylea), which is used to treat degenerative eye conditions, will be funded from 1 June 2018 and will be available in both hospitals and the community.
